BioCryst Pharmaceuticals is a biotechnology company that focuses on the development of novel oral and small-molecule drugs targeting rare diseases. They generate revenue through the commercialization of their FDA-approved treatments, such as Orladeyo for hereditary angioedema, and by advancing their robust pipeline of drug candidates. Founded in 1986, BioCryst has a significant history of innovation in antiviral and rare disease therapies, and they are known for their commitment to improving patient outcomes through scientific excellence.